Q-omics provides the consensus-scored PYM1 profile across patient tissues and cancer cell-line models. PYM1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, PYM1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PYM1 RNA expression shows 19,048 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, KIRC, and ACC as cancer lineages where PYM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PYM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PYM1 survival associations across molecular data types. PYM1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PYM1 RNA expression–survival associations across cancer types. High PYM1 expression shows unfavorable associations in LIHC, KICH, LAML, UVM, ACC and COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for PYM1 RNA expression.
This table summarizes PYM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PYM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PYM1 shows higher tumor expression in KIRC, BLCA, LIHC, KIRP, BRCA and LUAD. The KIRC box plot shows higher PYM1 RNA expression in tumor versus normal tissue (log2 FC = +0.633, t-test p < 0.001).
This table shows molecular features associated with PYM1 in patient tissues and cancer cell lines. In patient samples, PYM1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PYM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
